S3 Table. Sensitivity analysis of the study outcomes by excluding people with previous SARS-CoV-2 infection

| AESI                                      | First dose recipients |                       | Second dose recipients |                       |
|-------------------------------------------|-----------------------|-----------------------|------------------------|-----------------------|
|                                           | IRR                   | 95% CI                | P-value                | IRR                   | 95% CI                | P-value                |
| Overall AESI                              | 0.98                  | (0.89, 1.09)          | 0.726                  | 0.97                  | (0.87, 1.08)          | 0.546                  |
| Sleeping disturbance or disorder          | 0.66                  | (0.49, 0.88)          | 0.006                  | 0.91                  | (0.66, 1.27)          | 0.586                  |
| Acute aseptic arthritis                   | 1.33                  | (0.79, 2.24)          | 0.282                  | 1.13                  | (0.68, 1.90)          | 0.636                  |
| (Idiopathic) Thrombocytopenia             | 0.72                  | (0.24, 2.16)          | 0.556                  | -                     | -                     | -                     |
| Heart failure                             | 1.59                  | (0.94, 2.71)          | 0.083                  | 1.45                  | (0.77, 2.74)          | 0.255                  |
| Coronary artery disease                   | 1.13                  | (0.88, 1.44)          | 0.354                  | 1.13                  | (0.86, 1.47)          | 0.376                  |
| Arrhythmia                                | 0.90                  | (0.69, 1.17)          | 0.432                  | 0.96                  | (0.72, 1.27)          | 0.764                  |
| Thromboembolism                           | 0.94                  | (0.78, 1.14)          | 0.542                  | 0.93                  | (0.75, 1.15)          | 0.501                  |
| Hemorrhagic disease                       | 1.04                  | (0.67, 1.60)          | 0.870                  | 0.63                  | (0.38, 1.04)          | 0.070                  |
| Acute liver injury                        | 1.31                  | (0.57, 2.98)          | 0.523                  | 0.59                  | (0.21, 1.66)          | 0.317                  |
| Acute kidney injury                       | 2.24                  | (0.97, 5.16)          | 0.059                  | 0.79                  | (0.30, 2.06)          | 0.624                  |
| Acute pancreatitis                        | 1.08                  | (0.51, 2.30)          | 0.838                  | 1.62                  | (0.81, 3.24)          | 0.173                  |
| Generalized convulsion                     | 1.41                  | (0.92, 2.17)          | 0.117                  | 0.73                  | (0.43, 1.25)          | 0.250                  |
| Bell’s palsy                              | 1.95                  | (1.12, 3.41)          | 0.018                  | 0.88                  | (0.51, 1.51)          | 0.641                  |
| Acute respiratory distress syndrome       | 0.81                  | (0.40, 1.66)          | 0.571                  | 1.27                  | (0.76, 2.13)          | 0.360                  |
| Anaphylaxis                               | 0.34                  | (0.14, 0.79)          | 0.012                  | -                     | -                     | -                     |
| Sudden death                              | 0.97                  | (0.39, 2.38)          | 0.943                  | 1.80                  | (0.69, 4.73)          | 0.232                  |
| Rhabdomyolysis                            | 1.48                  | (0.46, 4.79)          | 0.513                  | -                     | -                     | -                     |
| Myocardial Infarction                     | 1.18                  | (0.87, 1.60)          | 0.287                  | 0.91                  | (0.65, 1.28)          | 0.604                  |
| Venous thromboembolism                    | 0.57                  | (0.26, 1.29)          | 0.180                  | -                     | -                     | -                     |
| Arterial thromboembolism                  | 1.02                  | (0.79, 1.33)          | 0.858                  | 1.12                  | (0.84, 1.50)          | 0.446                  |
| All-cause mortality                       | 0.96                  | (0.63, 1.48)          | 0.866                  | 0.85                  | (0.51, 1.40)          | 0.516                  |

Abbreviations: AESI=adverse event of special interest; CI=confidence interval; IRR=incidence rate ratio

Note: IRR was estimated only when there were at least five events for a specific AESI in both BNT162b2 and CoronaVac groups, respectively.